In a research report released Tuesday, Maxim analyst Jason Kolbert maintained a Buy rating on shares of OncoSec Medical Inc (NASDAQ:ONCS) with a $17.00 price target, after the company announced the enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec’s investigational therapy, ImmunoPulse IL-12, and Merck’s approved anti-PD-1 agent, KEYTRUDA in patients with unresectable metastatic melanoma.

Kolbert wrote, “IL-12 Immunopulse upregulation of IL-12 in the tumor itself may be the key to ‘unmasking’ tumors to T cell attack, potentially further enhanced by increased susceptibility to checkpoint inhibitors like anti-PD-1 monoclonal antibodies. Oncosec’s approach may be applicable to many tumor types, particularly those with a high incidence of anti-PD-1/PDL-1 nonresponders. The two trials may yield important clues as the role if IL-12 in the immunological ballet that occurs with Tumor cells.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of -7.7% and a 33.6% success rate. Kolbert has a -30.6% average return when recommending ONCS, and is ranked #3708 out of 3738 analysts.

2 analysts polled by TipRanks rate OncoSec Medical stock a Buy. With a return potential of 251%, the stock’s consensus target price stands at $21.